Development of firm’s heptagonists supported with $100,000 award.

PolyMedix received a phase 1 SBIR grant from the National Heart, Lung, and Blood Institute. The six-month, $100,000 backing will support the development of biomimetic compounds as anticoagulant antagonists.

PolyMedix says that it the funding will go toward the company’s continued efforts to develop new compounds as antagonists to heparin and low molecular weight heparin. It calls these compounds heptagonists.

PolyMedix hopes to file an IND application during the first quarter of 2008. Upon successful completion of the phase 1 portion of the work, PolyMedix plans to submit a request for additional funding.

This award reportedly is the fifth SBIR grant awarded to the company. Previous grants totaled $3.5 million and were given in support of antibiotic development.

Previous articleAcetylation Identified as Major Player in Signal Transduction
Next articleAvesthagen-Cipla Joint Venture Acquires Biologics-Focused CMO